Ocular Therapeutix (OCUL) News Today $8.56 +0.06 (+0.71%) (As of 05:26 PM ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 Time Period Barclays PLC Acquires 138,441 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Barclays PLC raised its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 37.1% in the third quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 511,522 shares of the biopharmaceutical company's stock after purchasing anDecember 22 at 3:55 AM | marketbeat.comState Street Corp Trims Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)State Street Corp trimmed its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 11.3% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 3,476,292 shares of the biopharmaceutical company'December 22 at 3:22 AM | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Rating of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has received a consensus rating of "Moderate Buy" from the seven brokerages that are presently covering the firm, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have given a buy recommendation toDecember 22 at 2:51 AM | marketbeat.comInvestors might be losing patience for Ocular Therapeutix's (NASDAQ:OCUL) increasing losses, as stock sheds 12% over the past weekDecember 19, 2024 | finance.yahoo.comWellington Management Group LLP Purchases 148,310 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Wellington Management Group LLP boosted its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 47.1% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 462,864 shares of the bioDecember 18, 2024 | marketbeat.comFmr LLC Purchases 428,335 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Fmr LLC lifted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 7,098.7% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 434,369 shares of the biopharmaceutical company's stoDecember 14, 2024 | marketbeat.comOcular Therapeutix™ Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)December 13, 2024 | globenewswire.comVerition Fund Management LLC Purchases Shares of 62,501 Ocular Therapeutix, Inc. (NASDAQ:OCUL)Verition Fund Management LLC acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm acquired 62,501 shares of the biopharmaceutical company's stock, valuDecember 12, 2024 | marketbeat.comOcular Therapeutix™ to Present at the 43rd Annual J.P. Morgan Healthcare ConferenceDecember 10, 2024 | globenewswire.comCharles Schwab Investment Management Inc. Has $9.66 Million Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Charles Schwab Investment Management Inc. increased its position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 146.6% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,110,460 shares of the bioDecember 10, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Shares Sold by Point72 Asset Management L.P.Point72 Asset Management L.P. lowered its stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 24.6% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 2,040,620 shares of the biopharmaDecember 7, 2024 | marketbeat.comPolar Asset Management Partners Inc. Makes New $4.29 Million Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Polar Asset Management Partners Inc. purchased a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm purchased 492,900 shares of the biopharmaceutical company's stock, valuedDecember 5, 2024 | marketbeat.comPromising Outlook for Ocular Therapeutix: Buy Rating Supported by Strong Market Demand and Financial ValuationDecember 4, 2024 | markets.businessinsider.comPatient Square Capital LP Makes New Investment in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Patient Square Capital LP bought a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 235,498 shares of theDecember 4, 2024 | marketbeat.comErste Asset Management GmbH Takes $2.05 Million Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Erste Asset Management GmbH acquired a new position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 235,800 shares of the biopharmaceutical cDecember 4, 2024 | marketbeat.comOcular Therapeutix announces over 300 subjects randomized in SOL-1December 2, 2024 | markets.businessinsider.comOcular Therapeutix™ Announces More Than 300 Subjects Randomized in SOL-1December 2, 2024 | globenewswire.comBraidwell LP Has $19.49 Million Stock Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Braidwell LP lifted its holdings in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 36.3% in the third quarter, according to its most recent 13F filing with the SEC. The institutional investor owned 2,239,770 shares of the biopharmaceutical company's stock after buying an additioNovember 29, 2024 | marketbeat.comKnoll Capital Management LLC Purchases 400,000 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Knoll Capital Management LLC boosted its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 199.6% in the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 600,400 shares of theNovember 29, 2024 | marketbeat.comJeffrey S. Heier Sells 2,948 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL) StockNovember 28, 2024 | insidertrades.comAcuta Capital Partners LLC Sells 1,581,059 Shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL)Acuta Capital Partners LLC cut its stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 57.1% during the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 1,190,071 shares of the biopharmaceutical company's stockNovember 28, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Receives Average Recommendation of "Moderate Buy" from AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been given a consensus recommendation of "Moderate Buy" by the seven brokerages that are presently covering the firm, Marketbeat Ratings reports. One investment analyst has rated the stock with a hold recommendation and six have given aNovember 27, 2024 | marketbeat.comOcular Therapeutix(TM) to Participate in December Investor and Scientific ConferencesNovember 26, 2024 | stockhouse.comOcular Therapeutix™ to Participate in December Investor and Scientific ConferencesNovember 26, 2024 | globenewswire.comBanco Santander S.A. Decreases Stock Position in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Banco Santander S.A. trimmed its position in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 54.4% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 172,231 shares of the biopharmaceutical company's stock after selling 205,137 sharNovember 23, 2024 | marketbeat.comOcular Therapeutix Reports Q3 2024 Financial ResultsNovember 17, 2024 | markets.businessinsider.comOcular Therapeutix (OCUL) Gets a Buy from ScotiabankNovember 16, 2024 | markets.businessinsider.comGSA Capital Partners LLP Purchases New Holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL)GSA Capital Partners LLP acquired a new position in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm acquired 126,681 shares of the biopharmaceutical company'sNovember 16, 2024 | marketbeat.comOcular Therapeutix Inc (OCUL) Q3 2024 Earnings Call Highlights: Strong Financial Position and ...November 16, 2024 | finance.yahoo.comOcular Therapeutix: Strategic Progress and Promising Pipeline Drive Buy RatingNovember 16, 2024 | markets.businessinsider.comOcular Therapeutix price target raised to $15 from $14 at H.C. WainwrightNovember 16, 2024 | markets.businessinsider.comHC Wainwright Raises Ocular Therapeutix (NASDAQ:OCUL) Price Target to $15.00HC Wainwright upped their price target on shares of Ocular Therapeutix from $14.00 to $15.00 and gave the stock a "buy" rating in a research note on Friday.November 15, 2024 | marketbeat.comQ3 2024 Ocular Therapeutix Inc Earnings CallNovember 15, 2024 | uk.finance.yahoo.comA Peek at Ocular Therapeutix's Future EarningsNovember 14, 2024 | benzinga.comOcular Therapeutix’s Clinical Progress and Strategic Trials Drive Buy RatingNovember 14, 2024 | markets.businessinsider.comOcular Therapeutix™ Reports Third Quarter 2024 Results and Business HighlightsNovember 14, 2024 | finance.yahoo.comOcular Therapeutix™ to Present at the Jefferies London Healthcare Conference and Ophthalmology Innovation Summit XIVNovember 13, 2024 | globenewswire.comOcular Therapeutix, Inc.: Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business OfficerNovember 13, 2024 | finanznachrichten.deOcular Therapeutix, Inc.: Ocular Therapeutix Appoints Namrata Saroj, OD, as Chief Business OfficerNovember 13, 2024 | finanznachrichten.deOcular Therapeutix appoints Saroj as Chief Business OfficerNovember 13, 2024 | markets.businessinsider.comOcular Therapeutix appoints Saroj as Chief Business OfficerNovember 13, 2024 | markets.businessinsider.comOcular Therapeutix (OCUL) Set to Announce Quarterly Earnings on ThursdayOcular Therapeutix (NASDAQ:OCUL) will be releasing earnings before the market opens on Thursday, November 14, Zacks reports.November 7, 2024 | marketbeat.comOcular Therapeutix™ to Report Third Quarter 2024 Results on November 14, 2024November 6, 2024 | globenewswire.comRosalind Advisors Inc. Grows Stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Rosalind Advisors Inc. increased its holdings in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) by 18.0% in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 885,000 shares of the biopharmaceutical cNovember 6, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Given Consensus Recommendation of "Moderate Buy" by AnalystsOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the seven brokerages that are covering the firm, MarketBeat Ratings reports. One investment analyst has rated the stock with a hold rating and six have issued a buy rating oNovember 2, 2024 | marketbeat.comOcular Therapeutix (NASDAQ:OCUL) Hits New 12-Month High - Should You Buy?Ocular Therapeutix (NASDAQ:OCUL) Sets New 52-Week High - Here's WhyOctober 28, 2024 | marketbeat.comOcular Therapeutix, Inc. (NASDAQ:OCUL) Sees Large Decrease in Short InterestOcular Therapeutix, Inc. (NASDAQ:OCUL - Get Free Report) was the recipient of a significant decline in short interest during the month of October. As of October 15th, there was short interest totalling 13,260,000 shares, a decline of 18.1% from the September 30th total of 16,190,000 shares. Based on an average trading volume of 1,160,000 shares, the days-to-cover ratio is currently 11.4 days.October 28, 2024 | marketbeat.comAssenagon Asset Management S.A. Invests $24.58 Million in Ocular Therapeutix, Inc. (NASDAQ:OCUL)Assenagon Asset Management S.A. bought a new stake in Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund bought 2,825,756 shares of the biopharmaceutical company'sOctober 26, 2024 | marketbeat.comPiper Sandler Remains a Buy on Ocular Therapeutix (OCUL)October 22, 2024 | markets.businessinsider.comSG Americas Securities LLC Purchases Shares of 45,187 Ocular Therapeutix, Inc. (NASDAQ:OCUL)SG Americas Securities LLC purchased a new stake in shares of Ocular Therapeutix, Inc. (NASDAQ:OCUL - Free Report) in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor purchased 45,187 shares of the biopharmaceutical company's stock,October 18, 2024 | marketbeat.com Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address 2025 AI Stock Picks: 2 Hidden Gems Under $10/Share (Ad)The AI sector continues to make waves as we move into 2025, and now is a prime opportunity to get involved—without stretching your budget! We’ve just uncovered 2 promising AI stocks trading for under $10/share, and they’re positioned for impressive growth in the coming months. 👉[Click here to get your FREE report delivered instantly!] OCUL Media Mentions By Week OCUL Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. OCUL News Sentiment▼0.970.59▲Average Medical News Sentiment OCUL News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. OCUL Articles This Week▼55▲OCUL Articles Average Week Get Ocular Therapeutix News Delivered to You Automatically Sign up to receive the latest news and ratings for OCUL and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies BBIO News Today TGTX News Today CRNX News Today VKTX News Today KRYS News Today ADMA News Today SRRK News Today APLS News Today ACLX News Today RARE News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:OCUL) was last updated on 12/23/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ocular Therapeutix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Ocular Therapeutix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free OCUL Stock Alerts